News

About 93 subjects at 38 centres in 14 countries were enrolled in PETIT2, a 2-part, double-blind, randomised placebo-controlled and open-label trial, which was designed to investigate the efficacy,

The tablets, a combination of 100mg aspirin and 15mg lansoprazole, are the first FDC drug in Japan to combine low-dose aspirin with a proton pump inhibitor. The company

Rilpivirine is a non-nucleoside reverse transcriptase inhibitor and is currently being marketed as Edurant, while dolutegravir is an integrase inhibitor marketed as Tivicay. If successfully developed and approved

The company secured final approval from the US Food and Drug Administration (FDA) for its abbreviated new drug application (ANDA) for this product, which is indicated to treat

At present there are few adequate and well-controlled studies of pharmacotherapy in preschool-age children with ADHD and the company is the process of developing design protocols for three

As part of the deal, MorphoSys and Merck’s biopharmaceutical division Merck Serono, will join forces to develop therapies that modulate the immune system’s natural ability to combat tumors.

After reviewing the company’s Clinical Trial Application, CCMO has provided a Letter of No Objection, and the Independent Ethics Committee of the Foundation "Evaluation of Ethics in Biomedical

NUVISAN is a fully integrated contract research organization providing clinical development and lab services to the global pharmaceutical industry. For over 30 years, NUVISAN has been assisting their

Ferrer, a privately-help Spanish pharmaceutical company, licensed US rights for Ozenoxacin to Medimetriks earlier this year. The multicenter, randomized, double-blinded, clinical study compares Ozenoxacin 1% cream versus placebo.